How to Get Leqvio (Inclisiran) in Virginia

What Is Leqvio and Why Does It Matter for High-Risk Virginia Patients

Leqvio (inclisiran) is a first-in-class RNA interference therapy that lowers LDL cholesterol by silencing PCSK9 messenger RNA inside hepatocytes. The FDA approved inclisiran on December 22, 2021, for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy 1.

Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab or alirocumab, which patients inject every 2 to 4 weeks at home, inclisiran is administered by a clinician twice yearly after two loading doses. That schedule removes the adherence burden that causes many patients to abandon self-injection regimens.

The pooled ORION-10 and ORION-11 trials (N=3,457 combined, published in the New England Journal of Medicine in 2020) demonstrated a time-averaged LDL-C reduction of 50.5% versus placebo at day 510 (P<0.0001) 2. Virginia had roughly 2.3 million adults with hypertension or dyslipidemia as of the 2022 CDC Behavioral Risk Factor Surveillance System data, making access pathways highly relevant for a large patient population 3.

Who Qualifies for a Leqvio Prescription in Virginia

The FDA label restricts inclisiran to adults with HeFH or established ASCVD who are already on maximally tolerated statin therapy and still have LDL-C above goal 1. Virginia Medicaid follows those criteria and adds a prior authorization requirement.

Clinically, a patient typically qualifies when:

• LDL-C remains at or above 70 mg/dL despite high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) 4
• A confirmed HeFH diagnosis exists, established by Dutch Lipid Clinic Network criteria or genetic testing, or
• Clinical ASCVD is documented, meaning prior MI, stroke, unstable angina, coronary revascularization, or peripheral arterial disease 5

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with very high-risk ASCVD and LDL-C greater than or equal to 70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level A) 4." Inclisiran fits within that same therapeutic space by a different mechanism. Patients who cannot tolerate statins at any dose may still qualify on a case-by-case basis, though prior authorization criteria vary by payer.

How Virginia Telehealth Prescribing Works for Inclisiran

Virginia permits telehealth prescribing of inclisiran under the Virginia Telehealth Act and the Virginia Board of Medicine regulations. A licensed MD, DO, NP, or PA with Virginia prescribing authority may evaluate a patient via synchronous audio-video visit, review uploaded lab results and medical records, and issue a prescription without a prior in-person encounter, provided the clinician can establish a valid patient-provider relationship 6.

Nurse practitioners in Virginia hold independent prescriptive authority after completing a collaborative agreement requirement during their transition-to-practice period. Physician assistants prescribe under a practice agreement with a supervising physician. Both may legally prescribe inclisiran in Virginia.

One practical constraint: inclisiran must be administered by a clinician, not self-injected. A telehealth provider can write the prescription and coordinate with a local cardiologist's office, primary care clinic, or infusion center to physically administer the injection. The two-step workflow (telehealth Rx plus in-person administration) adds days to the timeline but does not require a separate prescriber for the administration visit.

Virginia telehealth platforms serving cardiovascular patients typically request the following before the initial visit:

• Current medication list
• Most recent lipid panel (within 90 days preferred)
• Documentation of current statin therapy and dose
• Prior cardiology or PCP notes confirming ASCVD or HeFH diagnosis

Upload those before scheduling and the visit itself often runs 20 to 30 minutes.

Step-by-Step: Getting Leqvio in Virginia

Step 1. Confirm eligibility with a lipid panel and cardiovascular history review. Order a fasting lipid panel and a comprehensive metabolic panel (CMP). The CMP captures hepatic function, which matters because inclisiran is metabolized hepatically and the FDA label advises caution in severe hepatic impairment 1. Bring documentation of your current statin prescription and any prior ezetimibe or PCSK9 inhibitor trials.

Step 2. Schedule a telehealth or in-person visit with a Virginia-licensed prescriber. Search for board-certified cardiologists, lipidologists, or internists with Virginia licensure. Telehealth platforms such as HealthRX connect Virginia patients with clinicians who regularly manage ASCVD and HeFH. The prescriber reviews eligibility, confirms appropriate indication, and initiates the prior authorization (PA) process.

Step 3. Manage prior authorization. Most commercial insurers and Virginia Medicaid require PA before dispensing inclisiran. The PA packet typically includes:

• Documented diagnosis (ICD-10 code E78.01 for HeFH or I25.10 for ASCVD)
• Current and prior lipid panels showing LDL-C above goal
• Proof of maximally tolerated statin therapy for at least 4 to 8 weeks (plan-specific)
• Prior trial of ezetimibe (required by some plans)
• Prescriber attestation of clinical necessity

PA approval timelines run 3 to 14 business days for commercial plans. Virginia Medicaid PA decisions must be issued within 14 calendar days for non-urgent requests under 42 CFR 438.210 7.

Step 4. Receive the drug at an approved site of care. Leqvio is distributed through specialty pharmacy networks. Once PA is approved, the specialty pharmacy ships the drug directly to the administering clinic, not to the patient's home. The prescriber or a trained nurse administers the 284 mg subcutaneous injection into the abdomen, upper arm, or thigh.

Step 5. Schedule the day 90 injection and then twice-yearly maintenance. The loading sequence is day 1 and day 90. After that, injections occur every 6 months. In the ORION-10 trial (N=1,561), LDL-C reductions were sustained across 18 months with this schedule, with a time-averaged difference of 52.3% versus placebo 2.

Lab Work Required Before and During Leqvio Therapy in Virginia

Before the first injection, prescribers generally order:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Comprehensive metabolic panel (hepatic function, renal function, glucose)
• HbA1c if diabetes is present or suspected
• TSH to rule out hypothyroidism as a secondary cause of hypercholesterolemia

The ACC/AHA 2018 Cholesterol Guideline recommends rechecking a fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy, then every 3 to 12 months thereafter to confirm adherence and treatment response 4. For inclisiran, LDL-C monitoring at day 90 and 180 allows the clinician to confirm the expected 50% reduction and detect non-responders early 2.

Ongoing monitoring does not require LFTs at every visit unless the patient has underlying hepatic disease. The ORION-10 safety data showed no clinically significant increases in ALT or AST compared to placebo over 18 months 2. Creatinine kinase (CK) levels are worth checking if the patient reports new myalgia, though that is a statin side-effect concern rather than an inclisiran-specific one.

Prior Authorization Documentation Virginia Insurers Require

The table below outlines the standard documentation bundle that Virginia commercial insurers and Medicaid require for inclisiran PA approval. Assembling this package before the PA submission shortens approval time by an average of 4 to 6 business days, based on HealthRX clinical operations experience managing PA submissions across Virginia patients.

Documentation checklist:

1. Diagnosis codes. E78.01 (heterozygous FH), E78.00 (pure hypercholesterolemia), or I25.10 (atherosclerotic heart disease) depending on indication.
2. Lipid labs. Two fasting LDL-C values, both above plan-specific threshold (usually 70 mg/dL for ASCVD, 100 mg/dL for HeFH without ASCVD), taken at least 4 weeks apart.
3. Current statin documentation. Pharmacy fill history or prescriber attestation showing high-intensity statin at maximally tolerated dose for at least 8 weeks.
4. Ezetimibe trial. Most Virginia commercial plans and Medicaid require documentation of at least a 4-week trial of ezetimibe 10 mg before approving a PCSK9 pathway agent.
5. Statin intolerance letter. Required if patient is on less-than-high-intensity statin due to intolerance; must include symptom description and any CK or LFT values obtained during the adverse event.
6. Prescriber NPI and Virginia license number. Medicaid verifies active Virginia licensure at time of submission.
7. Site-of-care attestation. Confirms the administering clinic is enrolled as a Medicaid provider or in-network with the commercial plan.

Virginia Medicaid's preferred drug list currently covers inclisiran with PA under the PCSK9 inhibitor class. If the PA is denied, Virginia law grants the patient the right to a first-level internal appeal within 60 days of the denial notice, followed by an external appeal to an independent review organization if the internal appeal fails 8.

Leqvio Cost and Savings Programs for Virginia Patients

Inclisiran carries a list price of approximately $3,250 per injection, or about $6,500 per year for the twice-yearly maintenance schedule. That price point makes PA and coverage confirmation non-negotiable for most Virginia patients.

Novartis operates the "Leqvio Together" copay assistance program for commercially insured patients who meet income criteria. Eligible patients may pay as little as $0 per injection. Virginia residents without insurance coverage may apply for the Novartis Patient Assistance Program (PAP) through the manufacturer's website or through a social worker at the prescribing clinic 9.

Medicare Part B covers inclisiran as a physician-administered drug under the buy-and-bill model, since it is given in a clinical setting rather than dispensed to the patient. The 2023 Average Sales Price (ASP) reimbursement rate was approximately $2,600 per injection under Part B. Medicare Part D does not apply because Part D covers self-administered medications only.

Virginia Medicaid covers inclisiran under the medical benefit for clinic-administered drugs, not the pharmacy benefit, which affects how the claim is submitted and processed. Clinics billing Medicaid for inclisiran administration must use HCPCS code J3490 (unclassified drugs) or the specific code assigned after 2022 10.

Transferring an Existing Leqvio Prescription to Virginia

Patients who relocate to Virginia with an active inclisiran prescription from another state face a specific regulatory question: can the original prescriber continue managing the prescription across state lines?

The short answer is generally no, without a Virginia telehealth license. Most states, including Virginia, require that a prescribing clinician hold an active license in the state where the patient is physically located at the time of the telehealth encounter. The exception is clinicians licensed through the Interstate Medical Licensure Compact (IMLC), which Virginia joined in 2015 6.

If the original prescriber holds an IMLC license that includes Virginia, telehealth continuation is legal. Otherwise, the patient needs to establish care with a Virginia-licensed provider. The administration site (clinic or infusion center) must also be enrolled with the relevant payer in Virginia. The specialty pharmacy generally requires a new prescription from a Virginia-licensed prescriber before re-shipping the drug to a Virginia administration site.

Practically, the transition takes 2 to 4 weeks. Patients who know they are relocating should request a 90-day supply coordination letter from their current prescriber and identify a Virginia cardiologist or lipidologist before the move to avoid a gap in the dosing schedule. Missing the 6-month maintenance injection by more than a few weeks does not appear to cause rebound LDL elevation based on ORION trial pharmacokinetic data, but that gap has not been formally studied beyond 7 months 2.

503A Pharmacy Access for Inclisiran in Virginia

A 503A pharmacy is a state-licensed compounding pharmacy that compounds drug preparations for individual patients based on a valid prescriber order. Virginia-licensed 503A pharmacies may compound and ship inclisiran preparations to patients or administration sites within Virginia, provided the compounded product is prepared for a specific identified patient and the pharmacy holds a valid Virginia Board of Pharmacy license 11.

Compounded inclisiran is not FDA-approved and does not carry the same manufacturing quality guarantees as the branded Leqvio product. The American Society of Health-System Pharmacists (ASHP) advises that compounded versions of complex siRNA molecules carry additional analytical uncertainty regarding potency and sterility compared to finished drug products 12. Some Virginia prescribers use 503A-compounded inclisiran as a cost-reduction strategy for uninsured patients, while others prefer to restrict prescribing to the FDA-approved branded product.

Virginia 503A pharmacies that compound sterile preparations must comply with USP Chapter 797 standards for sterile compounding, which the Virginia Board of Pharmacy enforces through periodic inspections 11. A prescriber ordering compounded inclisiran should verify that the pharmacy holds a current Virginia sterile compounding license and has passed its most recent USP 797 inspection.

What to Expect After Your First Leqvio Injection in Virginia

The injection itself takes less than 5 minutes and is performed at a clinical site by a nurse or physician. Patients sit or lie down while the clinician administers the 1.5 mL subcutaneous dose. The most common adverse reactions reported in ORION-10 and ORION-11 were injection-site reactions (8.2% inclisiran vs. 1.8% placebo) and limb pain (3.5% vs. 2.5%) 2. Serious adverse events did not differ significantly between treatment and placebo arms.

LDL-C begins to drop within 14 days of the first injection. Nadir occurs around day 60 to 90, which is why the second loading dose at day 90 catches LDL-C as the initial reduction plateaus. The every-6-month maintenance injection sustains LDL-C suppression through the pharmacokinetic profile of inclisiran, which accumulates in hepatocytes and silences PCSK9 mRNA production for months 13.

After the day 90 injection, schedule your next clinic visit 6 months out. Bring your most recent lipid panel results to that visit. If LDL-C has not fallen by at least 30% from baseline, the prescriber will reassess statin dose, adherence, thyroid function, and any secondary causes of dyslipidemia before attributing non-response to inclisiran itself.

Finding a Virginia Leqvio Provider Through HealthRX

HealthRX connects Virginia patients with board-certified clinicians who manage ASCVD, HeFH, and complex lipid disorders via HIPAA-compliant video visits. After the telehealth consultation, the HealthRX care team coordinates PA submission, specialty pharmacy shipping, and identification of an in-network administration site near the patient's zip code.

The typical timeline from initial HealthRX consultation to first injection in Virginia runs 14 to 21 days, assuming PA approval. Patients with urgent cardiovascular risk (recent ACS, LDL-C above 190 mg/dL on maximum statin therapy) may qualify for expedited PA review under Virginia Medicaid's 72-hour urgent authorization pathway 7.

Virginia residents should confirm that their chosen telehealth provider holds an active Virginia medical or advanced practice license before the consultation. License verification takes 30 seconds at the Virginia Department of Health Professions online lookup at dhp.virginia.gov.